United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts

Autor: Raj Vuppalanchi, Mary F. Paine, Robin J. Marles, Steven J. Casper, Leonard B. Seeff, Bill J. Gurley, Hellen A. Oketch-Rabah, Tieraona Low Dog, Amy L. Roe, Jawad Ahmad, Scott A. Jordan, Gabriel I. Giancaspro, Andrew Stolz, Cynthia V. Rider, Christopher Koh, Richard Ko, Averell H. Sherker, Kan He, Jose Serrano, Robert J. Fontana, Herbert L. Bonkovsky, Víctor M. Navarro, Joseph M. Betz, Theertham P. Rao, Simona Rossi, Mahendra P. Kapoor
Jazyk: angličtina
Rok vydání: 2020
Předmět:
NAA
N-acetyl aspartate

EGCG
(–)‐epigallocatechin‐3‐gallate

CIH
Concanavalin A-induced hepatitis

Health
Toxicology and Mutagenesis

AST
aspartate aminotransferase

Green tea extract
010501 environmental sciences
Liver injury
Toxicology
01 natural sciences
Camellia sinensis
AUC
area under the curve

chemistry.chemical_compound
NIH
National Institutes of Health

0302 clinical medicine
Bolus (medicine)
Oral administration
TGF-beta
Transforming growth factor beta

DSAE
JS3 USP Dietary Supplements Admission Evaluations Joint Standard-Setting Subcommittee

LFT(s)
liver function test(s)

PK/PD
pharmacokinetics and pharmacodynamics

C
Catechin

2. Zero hunger
PAs
Pyrrolizidine Alkaloids

Traditional medicine
Regular Article
Catechin
Jaundice
Dietary supplements
ConA
Concanavalin A

3. Good health
COMT
catechol‐O‐methyltransferase

GT
green tea

CMC
chemistry
manufacturing
and controls

GCG
(–)‐gallocatechin‐3‐gallate

HPMC
Hydroxypropyl methylcellulose

LD50
lethal dose
median

NIDDK
National Institute of Diabetes and Digestive and Kidney Diseases

medicine.symptom
HDS
herbal dietary supplement

PDGTE
powdered decaffeinated green tea extract

Bw
body weight

DO
Diversity Outbred

FDA
United States Food and Drug Administration

EC
(–)‐epicatechin

ECG
(‐)‐epicatechin‐3‐gallate

CG
(+)‐catechin‐3‐gallate

MGTT
Minnesota Green Tea Trial

NOAEL
no observed adverse effect level

DILI
drug‐induced liver injury

EFSA
European Food Safety Authority

ADME
Absorption
distribution
metabolism
and excretion

γ-GT
Gamma-glutamyl transferase

GTEH
EP Green Tea Extract Hepatotoxicity Expert Panel

USP
United States Pharmacopeia

MRL
maximum residue limit

NTP
National Toxicology Program

03 medical and health sciences
SIDS
single-ingredient dietary supplement

lcsh:RA1190-1270
ALT
alanine aminotransferase

OSM
online supplementary material

medicine
PD-1
Programmed death domain-1

Adverse effect
RUCAM
Roussel Uclaf Causality Assessment Method

0105 earth and related environmental sciences
lcsh:Toxicology. Poisons
LT(s)
Liver test(s)

ALP
alkaline phosphatase

business.industry
Hepatotoxicity
GT(E)
green tea or green tea extract

Green tea
medicine.disease
Bioavailability
CAM
causality assessment method

GTE
green tea extract

MIDS
multi-ingredient dietary supplement

chemistry
EGC
(–)‐epigallocatechin

DS
Dietary Supplement

GC
(+)‐gallocatechin

DILIN
Drug‐Induced Liver Injury Network

business
030217 neurology & neurosurgery
Zdroj: Toxicology Reports, Vol 7, Iss, Pp 386-402 (2020)
Toxicology Reports
ISSN: 2214-7500
Popis: As part of the United States Pharmacopeia’s ongoing review of dietary supplement safety data, a new comprehensive systematic review on green tea extracts (GTE) has been completed. GTEs may contain hepatotoxic solvent residues, pesticide residues, pyrrolizidine alkaloids and elemental impurities, but no evidence of their involvement in GTE-induced liver injury was found during this review. GTE catechin profiles vary significantly with manufacturing processes. Animal and human data indicate that repeated oral administration of bolus doses of GTE during fasting significantly increases bioavailability of catechins, specifically EGCG, possibly involving saturation of first-pass elimination mechanisms. Toxicological studies show a hepatocellular pattern of liver injury. Published adverse event case reports associate hepatotoxicity with EGCG intake amounts from 140 mg to ∼1000 mg/day and substantial inter-individual variability in susceptibility, possibly due to genetic factors. Based on these findings, USP included a cautionary labeling requirement in its Powdered Decaffeinated Green Tea Extract monograph that reads as follows: “Do not take on an empty stomach. Take with food. Do not use if you have a liver problem and discontinue use and consult a healthcare practitioner if you develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice (yellowing of the skin or eyes).”
Databáze: OpenAIRE